Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-5 of 5
Keywords: Golimumab
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Subject Area:
Article Collection: Short- and Long-term Real-World Outcomes of Advanced Therapies for Inflammatory Bowel Disease (IBD)
,
Gastroenterology
Daisuke Hirayama, Satoshi Motoya, Toshifumi Ashida, Katsuyoshi Ando, Mikihiro Fujiya, Takahiro Ito, Shigeru Furukawa, Atsuo Maemoto, Takehiko Katsurada, Shiro Hinotsu, Noriko Sato, Naomi Mizuno, Yoshiko Ikawa, Hiroshi Nakase
Journal:
Inflammatory Intestinal Diseases
Inflamm Intest Dis (2023) 8 (3): 115–127.
Published Online: 31 August 2023
... of golimumab (GLM) in Japanese patients with ulcerative colitis (UC) in real clinical practice. This study aimed to explore the real-life effectiveness and factors associated with response to GLM in Japanese patients with UC. Methods: This observational, retrospective, multicenter study was conducted...
Journal Articles
Subject Area:
Gastroenterology
Journal:
Inflammatory Intestinal Diseases
Inflamm Intest Dis (2022) 7 (3-4): 155–162.
Published Online: 28 March 2023
...Katsumasa Nagano; Yuya Imai; Yoshifumi Ukyo; Taku Kobayashi; Seiji Yokoyama Introduction: Golimumab (GLM) is an anti-tumor necrosis factor-alpha antibody therapy for moderately to severely active ulcerative colitis (UC). Endoscopic improvement is considered one of UC treatment’s main goals...
Journal Articles
Subject Area:
Gastroenterology
Journal:
Inflammatory Intestinal Diseases
Inflamm Intest Dis (2022) 7 (3-4): 128–138.
Published Online: 28 March 2023
...Shiro Nakamura; Teita Asano; Yoshihito Tanaka; Kanami Sugimoto; Shinichi Yoshigoe; Yasuo Suzuki Introduction: Real-world evidence for the effectiveness and safety of golimumab (GLM) in patients with ulcerative colitis (UC) is limited. The aim of this study was to investigate the 52-week...
Journal Articles
Subject Area:
Gastroenterology
Journal:
Inflammatory Intestinal Diseases
Inflamm Intest Dis (2021) 6 (2): 117–122.
Published Online: 13 April 2021
... Golimumab Ulcerative colitis (UC) is a chronic inflammatory disease of the colon and rectum with repeated cycles of remission and relapse [ 1 ]. UC and Crohn’s disease (CD) are the 2 major forms of inflammatory bowel disease (IBD). The etiology of UC remains unknown. Treatment is determined...
Journal Articles
Subject Area:
Gastroenterology
Journal:
Inflammatory Intestinal Diseases
Inflamm Intest Dis (2017) 2 (2): 131–138.
Published Online: 19 October 2017
...Linda Russi; Michael Scharl; Gerhard Rogler; Luc Biedermann Background: The TNF-α antagonist golimumab is approved for the treatment of ulcerative colitis but not for Crohn's disease (CD). We herein report a case series of 8 difficult-to-treat patients with severe and refractory CD receiving...